Overview

A Single Dose Study Of PF-06678552 In Healthy Subjects

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
PF-06678552 is a new compound proposed for the treatment of hypercholesteremia. The primary purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of PF-06678552 in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer